Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2

Biomedit︠s︡inskai︠a︡ khimii︠a︡
A A Spasov, N I Chepljaeva

Abstract

This review summarizes data on the main approaches used for the search of biologically active compounds modulating the level and physiological activity of incretins. Currently two groups of drugs are used in clinical practice: they either replenish the deficit of incretins (glucagon-like peptide-1 receptor agonists) or inhibit the degradation processes (dipeptidyl peptidase 4 inhibitors). In addition, new groups of substances are actively searched. These include non-peptide agonists of glucagon-like peptide-1 receptors, agonists/antagonists of glucose-dependent insulinotropic peptide, the hybrid polypeptides based on glucagon-like peptide-1 and glucagon.

References

Jul 1, 1996·Diabetes Research and Clinical Practice·L S GolfmanN S Dhalla
Mar 1, 1997·Diabetes Research and Clinical Practice·Y SuzukiK Matsuoka
Aug 28, 2003·Current Opinion in Chemical Biology·Jonathan S Rosenblum, John W Kozarich
Jul 27, 2006·The Annals of Pharmacotherapy·Shannon Miller, Erin L St Onge
Oct 21, 2006·Biochemical Society Transactions·P R Flatt, B D Green
Jan 4, 2007·The Journal of Clinical Investigation·Daniel J Drucker
Jan 11, 2007·Proceedings of the National Academy of Sciences of the United States of America·Desu ChenMing-Wei Wang
Feb 20, 2007·Pharmacology & Therapeutics·Máire E Doyle, Josephine M Egan
May 18, 2007·Endocrinology·S R Murthy Madiraju, Vincent Poitout
Oct 3, 2007·The AAPS Journal·Irene TomClark Q Pan
Nov 27, 2007·British Journal of Pharmacology·H A OvertonC Reynet
Feb 29, 2008·Clinical Chemistry and Laboratory Medicine : CCLM·Patrick Braun
Apr 23, 2008·Endocrinology·L LaufferP L Brubaker
Sep 25, 2008·The Journal of Clinical Endocrinology and Metabolism·Jessica E MatthewsUNKNOWN Albiglutide Study Group
Dec 17, 2008·Pharmacological Reviews·Wook Kim, Josephine M Egan
Sep 15, 2009·Best Practice & Research. Clinical Endocrinology & Metabolism·Nancy A Thornberry, Baptist Gallwitz
Sep 15, 2009·Best Practice & Research. Clinical Endocrinology & Metabolism·Nigel Irwin, Peter R Flatt
Nov 26, 2009·Expert Opinion on Pharmacotherapy·Jay H ShubrookFrank L Schwartz
Feb 5, 2010·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Baptist Gallwitz
Mar 23, 2010·European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology·Maria do Carmo Pereira NunesManoel O C Rocha
Apr 29, 2010·Current Diabetes Reports·Bart StaelsVivian Fonseca
Sep 24, 2010·Drug News & Perspectives·Shalinee Dhayal, Noel G Morgan
Dec 7, 2010·Trends in Pharmacological Sciences·George TharakanStephen Bloom
Dec 15, 2010·Journal of Hepatology·Thijs W H PolsKristina Schoonjans
Dec 25, 2010·Pharmaceutical Research·Renger F Witkamp
Mar 16, 2011·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Jason Seewoodhary, Stephen C Bain
Jun 22, 2011·Digestive Diseases·Thijs W H PolsKristina Schoonjans
Jul 15, 2011·Experimental Diabetes Research·Xiaosong ChenWendong Huang
Oct 26, 2011·Journal of Pharmacology & Pharmacotherapeutics·Darshan J Dave
Jan 21, 2012·The Review of Diabetic Studies : RDS·Alan J Garber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.